Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone

Blood

Volumn 102, Issue 5, 2003, Pages 1583-1587

  Cohen, Alan R ^a   Galanello, Renzo ^b   Piga, Antonio ^b   De Sanctis, Vinconzo ^b   Tricta, Fernando ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DEFERIPRONE; DEFEROXAMINE; ENALAPRIL; FERRITIN; IRON CHELATE; LIVER ENZYME;

ABDOMINAL PAIN; ADULT; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTHROPATHY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDEMA; ELEVATED LIVER ENZYME; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATITIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IRON OVERLOAD; KNEE PAIN; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; THALASSEMIA MAJOR; THROMBOCYTOPENIA; VOMITING;

EID: 0042943205     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3280     Document Type: Article

References (19)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761.
2. Cohen AR, Porter JB. Transfusion and iron chelation therapy in thalassemia and sickle cell anemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin. Cambridge, United Kingdom: Cambridge University Press; 2001:979-1027.
3. Porter JB. Practical management of iron overload. Brit J Haematol. 2001;115:239-252.
4. Olivieri NO, Nathan DG, MacMillan JH, et al. Survival of medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331:574-578.
5. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-573.
6. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematologica. 1996;95:26-36.
7. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051-2052.
8. Cohen A, Galanello R, Piga A, Vullo C, Tricta F. A multi-center safety trial of the oral iron chelator deferiprone. Ann N Y Acad Sci. 1998;850:223-226.
9. Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Brit J Haematol. 2000;108:305-312.
10. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417-423.
11. Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. Eur J Clin Pharmacol. 2001;56:915-922.
12. Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Brit J Haematol. 1995;91:224-229.
13. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332:918-922.
14. Maggio AM, D'Amico GD, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28:196-208.
15. Hoffbrand AV, Bartlett AN, Yeys PA, O'Connor NTJ, Kontoghiorges GJ. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anemia during oral chelator trial. Lancet. 1989;2:457.
16. Al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol. 1994;53:298-301.
17. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Brit J Haematol. 2002;118:330-336.
18. Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Brit J Haematol. 1992; 82:460-466.
19. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Brit J Haematol. 1998;103:361-364.